Leukemia Clinical Trials in Baltimore

Showing 1461-1480 of 1,652 trials

Expanded Dryvax Dilution Study in Previously Vaccinated Adults

NCT00050505

The purpose of this study is to determine the safety and effect of diluting smallpox vaccine, making a larger number of doses in case smallpox is released into the environment. A total of up to 927 healthy adults between the ages of 32 and 70 years who were already vaccinated against smallpox (but not since 1989) will volunteer for this study for up to 34 weeks and receive different strengths of vaccine. Some subjects may participate for longer if they choose to be revaccinated because the first vaccination does not take. The vaccine will be given by making small cuts in the skin and putting the vaccine into these cuts. After the screening visit, volunteers will be followed through study visits and follow up phone calls. Blood will be collected during some study visits to look at the immune system (body system that fights infection) response.

Smallpox

National Institute of Allergy and Infectious Diseases (NIAID)927 participantsStarted Oct 2002

Oakland, California, United States • Stanford, California, United States • Torrance, California, United States +4 more locations

TERMINATEDPhase 3< 1 mile

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

NCT01650805

The purpose of this study is to compare the efficacy of ponatinib and imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.

Chronic Myeloid Leukemia

Ariad Pharmaceuticals307 participantsStarted Jun 2012

Burbank, California, United States • Los Angeles, California, United States • Pleasant Hill, California, United States +167 more locations

Expanded Dryvax Dilution Study in Previously Vaccinated Adults

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Leukemia Trials in Other Cities

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia

Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia

Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia

A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer

Assessment of Right Ventricular Volume in Tetralogy of Fallott (TOF) Patients

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML

A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.

Other Conditions in Baltimore